Review



clone 1a8  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Bio X Cell clone 1a8
    αCD16-Ova–induced T-cell expansion in the spleen requires neutrophils and MHC on neutrophils, whereas Batf3 + cDC1s and splenic macrophages are dispensable. Mice were treated as in , and the role of neutrophils ( A and B ), MHC-I on neutrophils ( C and D ), and the contribution of cDC1 ( E and F ) and splenic macrophages ( G and H ) in αCD16-Ova–mediated T-cell proliferation was evaluated. A and B, Role of neutrophils. Treatment with <t>1A8</t> resulted in marked neutrophil depletion in blood but only partial depletion in the spleen ( A ), with a corresponding partial reduction in splenic CD8 OT-I and CD4 OT-II T-cell proliferation ( B ). C and D, Requirement for neutrophil MHC-I. In CD16B/γ −/− mice with neutrophil-specific MHC-I deletion <t>(Ly6G-Cre/MHC-I</t> fl/fl ), MHC-I expression was partially reduced on splenic neutrophils but intact on cDC1s ( C ); isotype control was used to set gates. CD8 OT-I proliferation was proportionally reduced in Ly6G-Cre/MHC-I fl/fl , consistent with incomplete MHC-I deletion in neutrophils ( D ). E and F, Requirement for Batf3 + cDC1s. In CD16B/γ −/− mice with a deletion in Batf3 (CD16B/γ −/− Batf3 −/− ), there was a marked loss of cDC1 but intact cDC2 populations ( E ). cDC1 loss did not affect αCD16-Ova induced CD8 OT-I or CD4 OT-II T-cell proliferation ( F ). G and H, Anti-CD115 antibody–mediated immunodepletion resulted in a significant but partial reduction of F4/80 + macrophages in the spleen compared with isotype control I (Ctr) treatment ( G ). CD115 antibody treatment did not alter αCD16-Ova–induced CD8 T-cell proliferation ( H ). Sp, spleen. Data are presented as mean ± SEM. Two-group comparisons were done using an unpaired two-tailed Student t test; comparisons among ≥3 groups were done using one-way ANOVA with Tukey post hoc test. Significance was defined as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Ab, antibody; KO, knockout.
    Clone 1a8, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 69 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/clone+1a8/InVivoPlus+anti-mouse+Ly6G+Ly6C/pmc13012031-73-10-12
    Average 95 stars, based on 69 article reviews
    clone 1a8 - by Bioz Stars, 2026-11
    95/100 stars

    Images

    1) Product Images from "Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity"

    Article Title: Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity

    Journal: Cancer Research Communications

    doi: 10.1158/2767-9764.CRC-25-0509

    αCD16-Ova–induced T-cell expansion in the spleen requires neutrophils and MHC on neutrophils, whereas Batf3 + cDC1s and splenic macrophages are dispensable. Mice were treated as in , and the role of neutrophils ( A and B ), MHC-I on neutrophils ( C and D ), and the contribution of cDC1 ( E and F ) and splenic macrophages ( G and H ) in αCD16-Ova–mediated T-cell proliferation was evaluated. A and B, Role of neutrophils. Treatment with 1A8 resulted in marked neutrophil depletion in blood but only partial depletion in the spleen ( A ), with a corresponding partial reduction in splenic CD8 OT-I and CD4 OT-II T-cell proliferation ( B ). C and D, Requirement for neutrophil MHC-I. In CD16B/γ −/− mice with neutrophil-specific MHC-I deletion (Ly6G-Cre/MHC-I fl/fl ), MHC-I expression was partially reduced on splenic neutrophils but intact on cDC1s ( C ); isotype control was used to set gates. CD8 OT-I proliferation was proportionally reduced in Ly6G-Cre/MHC-I fl/fl , consistent with incomplete MHC-I deletion in neutrophils ( D ). E and F, Requirement for Batf3 + cDC1s. In CD16B/γ −/− mice with a deletion in Batf3 (CD16B/γ −/− Batf3 −/− ), there was a marked loss of cDC1 but intact cDC2 populations ( E ). cDC1 loss did not affect αCD16-Ova induced CD8 OT-I or CD4 OT-II T-cell proliferation ( F ). G and H, Anti-CD115 antibody–mediated immunodepletion resulted in a significant but partial reduction of F4/80 + macrophages in the spleen compared with isotype control I (Ctr) treatment ( G ). CD115 antibody treatment did not alter αCD16-Ova–induced CD8 T-cell proliferation ( H ). Sp, spleen. Data are presented as mean ± SEM. Two-group comparisons were done using an unpaired two-tailed Student t test; comparisons among ≥3 groups were done using one-way ANOVA with Tukey post hoc test. Significance was defined as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Ab, antibody; KO, knockout.
    Figure Legend Snippet: αCD16-Ova–induced T-cell expansion in the spleen requires neutrophils and MHC on neutrophils, whereas Batf3 + cDC1s and splenic macrophages are dispensable. Mice were treated as in , and the role of neutrophils ( A and B ), MHC-I on neutrophils ( C and D ), and the contribution of cDC1 ( E and F ) and splenic macrophages ( G and H ) in αCD16-Ova–mediated T-cell proliferation was evaluated. A and B, Role of neutrophils. Treatment with 1A8 resulted in marked neutrophil depletion in blood but only partial depletion in the spleen ( A ), with a corresponding partial reduction in splenic CD8 OT-I and CD4 OT-II T-cell proliferation ( B ). C and D, Requirement for neutrophil MHC-I. In CD16B/γ −/− mice with neutrophil-specific MHC-I deletion (Ly6G-Cre/MHC-I fl/fl ), MHC-I expression was partially reduced on splenic neutrophils but intact on cDC1s ( C ); isotype control was used to set gates. CD8 OT-I proliferation was proportionally reduced in Ly6G-Cre/MHC-I fl/fl , consistent with incomplete MHC-I deletion in neutrophils ( D ). E and F, Requirement for Batf3 + cDC1s. In CD16B/γ −/− mice with a deletion in Batf3 (CD16B/γ −/− Batf3 −/− ), there was a marked loss of cDC1 but intact cDC2 populations ( E ). cDC1 loss did not affect αCD16-Ova induced CD8 OT-I or CD4 OT-II T-cell proliferation ( F ). G and H, Anti-CD115 antibody–mediated immunodepletion resulted in a significant but partial reduction of F4/80 + macrophages in the spleen compared with isotype control I (Ctr) treatment ( G ). CD115 antibody treatment did not alter αCD16-Ova–induced CD8 T-cell proliferation ( H ). Sp, spleen. Data are presented as mean ± SEM. Two-group comparisons were done using an unpaired two-tailed Student t test; comparisons among ≥3 groups were done using one-way ANOVA with Tukey post hoc test. Significance was defined as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Ab, antibody; KO, knockout.

    Techniques Used: Expressing, Control, Immunodepletion, Two Tailed Test, Knock-Out

    Related Articles

    Control:

    Article Title: Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit Polyclonal anti-human H3K27ac Abcam Cat# ab4729; RRID: AB_2118291 Rabbit Monoclonal anti-human YY1 (SY29-01) Invitrogen Cat# MA5-32052; RRID: AB_2809346 Rat monoclonal IgG2b isotype control (clone LTF-2) Bioxcell Cat#BE0090; RRID: AB_1107780 Rat monoclonal anti-mouse CD4 (clone GK1.5) Bioxcell Cat#BE0003-1; RRID: AB_1107636 Rat monoclonal anti-mouse CD8α (clone 2.43) Bioxcell Cat#BE0061; RRID: AB_1125541 Rat monoclonal anti-mouse CD8β (Lyt 3.2, clone 53-5.8) Bioxcell Cat#BE0223; RRID: AB_2687706 Rat monoclonal anti-mouse CD19 (clone 1D3) Bioxcell Cat#BE0150; RRID: AB_10949187 Rat monoclonal anti-mouse NK1.1 (clone PK136) Bioxcell Cat#BE0036; RRID: AB_1107737 Rat monoclonal anti-mouse CSF1R (CD115, clone AFS98) Bioxcell Cat#BE0213; RRID: AB_2687699 Rat monoclonal anti-mouse Ly6G (clone 1A8) Bioxcell CatBE0075-1; RRID: AB_1107721 Rat monoclonal anti-mouse CTLA-4 (CD152, clone 9D9) Bioxcell Cat#BE0164; RRID: AB_10949609 Rat monoclonal anti-mouse PD-1 (CD279) clone 29F.1A12 Bioxcell Cat#BE0273; RRID: AB_2687796 Rat monoclonal anti-mouse IFNAR-1 clone MAR1-5A3 Bioxcell Cat#BE0241; RRID: AB_2687723 Rat monoclonal anti-mouse IFNγ clone XMG1.2 Bioxcell Cat#BE0055; RRID: AB_1107694 Armenian hamster anti-mouse Fas Ligand (CD178) clone MFL3 Bioxcell Cat#BE0319; RRID: AB_2819046 Rabbit polyclonal anti-GFP Abcam Cat#ab6556; RRID: AB_305564 Rabbit monoclonal anti-mouse Fas clone EPR24898-74 Abcam Cat#ab271016 RRID: AB_3712731 Goat anti-rabbit labeled polymer EnVisionTM+ System Dako Cat#K400311-2 Rabbit monoclonal anti-mouse CD8α clone D4W2Z Cell Signaling Cat#98941 RRID:AB_2756376 Rabbit monoclonal anti-mouse FoxP3 clone D608R Cell Signaling Cat#12653 RRID: AB_2797979 Rabbit monoclonal anti-mouse CD31 clone D8V9E Cell Signaling Cat#77699 RRID: AB_2722705 Rabbit monoclonal anti-mouse ICAM1 clone EPR16608 Abcam Cat#ab179707 RRID:AB_2814769 Rat monoclonal anti-mouse CD4 BUV496 clone GK1.5 BD Biosciences Cat#612952; RRID: AB_2813886 Rat monoclonal anti-mouse CD8α BUV395 clone 53-6.7 BD Biosciences Cat# 563786; RRID: AB_2732919 (Continued on next page) e1 Cancer Cell 44, 1–17.e1–e12, May 11, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER Mouse monoclonal anti-human/mouse Granzyme B Pacific Blue clone GB11 Biolegend Cat# 515408 RRID: AB_2562196 Rat monoclonal anti-mouse Ly-6C FITC clone HK1.4 Biolegend Cat# 128006 RRID: AB_1186134 Rat monoclonal anti-mouse Ly-6G PE clone 1A8 Biolegend Cat# 127608 RRID: AB_1186104 Mouse monoclonal anti-mouse NK1.1 PE clone PK136 Biolegend Cat# 108707 RRID: AB_313394 Mouse monoclonal anti-mouse NK1.1 BV785 clone PK136 Biolegend Cat# 108749 RRID: AB_2564304 Mouse monoclonal anti-mouse NK1.1 BUV661 clone PK136 BD Biosciences Cat# 741477 RRID: AB_2870942 Armenian hamster anti-mouse TCRβ chain APC clone H57-597 Biolegend Cat# 109211 RRID: AB_313434 Armenian hamster anti-mouse TCRβ chain BV650 clone H57-597 Biolegend Cat# 109251 RRID: AB_2810348 Armenian hamster anti-mouse TCRβ chain BV421 clone H57-597 Biolegend Cat# 109230 RRID: AB_ 2562562 Rat monoclonal anti-mouse TNF-α BV421 clone MP6-XT22 Biolegend Cat# 506327 RRID: AB_2562902 Bacterial and virus strains Subcloning EfficiencyTM DH5α Invitrogen Cat#18265017 Chemicals, peptides, and recombinant proteins Cytofix/Cytoperm fixation permeabilization kit BD Biosciences Cat#554714 cOmpleteTM, EDTA-free Protease Inhibitor Cocktail Merck Cat#11873580001 PhosSTOP, Phosphatase Inhibitors Merck Cat#4906845001 Zombie NIR Fixable viability Kit BioLegend Cat#423106 PMA SIGMA Cat#P1585 Ionomycin calcium salt SIGMA Cat#I0634 Protein Transport Inhibitor (containing Brefeldin A) BD Biosciences Cat#555029 IQTM SYBR Green Supermix BIO-RAD Cat#1708882 Lymphoprep STEMCELL Technologies Cat#15257179 MACS SmartStrainer (70um) Miltenyi Biotec Cat#130-098-462 D-Luciferin Promega Cat#L2916 A485 MCE Cat#HY-107455 PEI 25 kDa Sigma Cat#408727 PEG8000 Sigma Aldrich Cat#P5413 OPTIPREP (Iodixanol) Axis Shield Cat#415468 Ultra-15 mL Amicon® columns Millipore Cat#C7715 OptiprepTM Serumwerk Bernburg Cat#1893 ACK Lysing Buffer Invitrogen Cat# A1049201 Collagenase D Roche Cat# 11088866001 DNAse I Roche 11 284 932 001 DMEM with Glutamax Gibco Cat# 61965-026 OptiMEM Gibco Cat #51985026 Lipofectamine3000 Invitrogen Cat# L3000 Formaldehide PanReac AppliChem Cas 50-00-0 Eukitt® Quick-hardening mounting medium Sigma-Aldrich Cat#03989 Cas 25608-33-7 (Continued on next page) e3 Cancer Cell 44, 1–17.e1–e12, May 11, 2026

    Article Title: Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity
    Article Snippet: .. CD16B-CD32A +/− /γ +/− male mice received 350 μg/mouse anti-Ly6G (clone 1A8, Bio X Cell, cat. #BP0075-1) for neutrophil depletion or isotype control rat IgG2a, κ (clone 2A3, Bio X Cell, cat. #BP0089) intraperitoneally on days −2 and −1 prior to OTI/OTII injection, then every 2 days thereafter. .. CD16B-CD32A +/− /γ +/− male mice received 350 μg/mouse anti-Ly6G (clone 1A8, Bio X Cell, cat. #BP0075-1) for neutrophil depletion or isotype control rat IgG2a, κ (clone 2A3, Bio X Cell, cat. #BP0089) intraperitoneally on days −2 and −1 prior to OTI/OTII injection, then every 2 days thereafter.

    Article Title: Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Anti-Tumor Immunity
    Article Snippet: .. D ow nloaded from http://aacrjournals.org/cancerrescom m un/article-pdf/doi/10.1158/2767-9764.C R C -25-0509/3736552/crc-25-0509.pdf by guest on 16 February 2026 8 Cell depletion in vivo CD16B-CD32A+/−/γ+/− male mice received 350 μg/mouse anti-Ly6G (clone 1A8, BioXCell Cat# BP0075-1) for neutrophil depletion or isotype control rat IgG2a, κ (clone 2A3, BioXcell Cat# BP0089) i.p. on days -2 and -1 prior to OTI/OTII injection, then every 2 days thereafter. .. Depletion was confirmed in the spleen and peripheral blood by flow cytometry using intracellular staining of anti-Ly6G (BioLegend Cat# 127612, RRID:AB_2251161).

    Labeling:

    Article Title: Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit Polyclonal anti-human H3K27ac Abcam Cat# ab4729; RRID: AB_2118291 Rabbit Monoclonal anti-human YY1 (SY29-01) Invitrogen Cat# MA5-32052; RRID: AB_2809346 Rat monoclonal IgG2b isotype control (clone LTF-2) Bioxcell Cat#BE0090; RRID: AB_1107780 Rat monoclonal anti-mouse CD4 (clone GK1.5) Bioxcell Cat#BE0003-1; RRID: AB_1107636 Rat monoclonal anti-mouse CD8α (clone 2.43) Bioxcell Cat#BE0061; RRID: AB_1125541 Rat monoclonal anti-mouse CD8β (Lyt 3.2, clone 53-5.8) Bioxcell Cat#BE0223; RRID: AB_2687706 Rat monoclonal anti-mouse CD19 (clone 1D3) Bioxcell Cat#BE0150; RRID: AB_10949187 Rat monoclonal anti-mouse NK1.1 (clone PK136) Bioxcell Cat#BE0036; RRID: AB_1107737 Rat monoclonal anti-mouse CSF1R (CD115, clone AFS98) Bioxcell Cat#BE0213; RRID: AB_2687699 Rat monoclonal anti-mouse Ly6G (clone 1A8) Bioxcell CatBE0075-1; RRID: AB_1107721 Rat monoclonal anti-mouse CTLA-4 (CD152, clone 9D9) Bioxcell Cat#BE0164; RRID: AB_10949609 Rat monoclonal anti-mouse PD-1 (CD279) clone 29F.1A12 Bioxcell Cat#BE0273; RRID: AB_2687796 Rat monoclonal anti-mouse IFNAR-1 clone MAR1-5A3 Bioxcell Cat#BE0241; RRID: AB_2687723 Rat monoclonal anti-mouse IFNγ clone XMG1.2 Bioxcell Cat#BE0055; RRID: AB_1107694 Armenian hamster anti-mouse Fas Ligand (CD178) clone MFL3 Bioxcell Cat#BE0319; RRID: AB_2819046 Rabbit polyclonal anti-GFP Abcam Cat#ab6556; RRID: AB_305564 Rabbit monoclonal anti-mouse Fas clone EPR24898-74 Abcam Cat#ab271016 RRID: AB_3712731 Goat anti-rabbit labeled polymer EnVisionTM+ System Dako Cat#K400311-2 Rabbit monoclonal anti-mouse CD8α clone D4W2Z Cell Signaling Cat#98941 RRID:AB_2756376 Rabbit monoclonal anti-mouse FoxP3 clone D608R Cell Signaling Cat#12653 RRID: AB_2797979 Rabbit monoclonal anti-mouse CD31 clone D8V9E Cell Signaling Cat#77699 RRID: AB_2722705 Rabbit monoclonal anti-mouse ICAM1 clone EPR16608 Abcam Cat#ab179707 RRID:AB_2814769 Rat monoclonal anti-mouse CD4 BUV496 clone GK1.5 BD Biosciences Cat#612952; RRID: AB_2813886 Rat monoclonal anti-mouse CD8α BUV395 clone 53-6.7 BD Biosciences Cat# 563786; RRID: AB_2732919 (Continued on next page) e1 Cancer Cell 44, 1–17.e1–e12, May 11, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER Mouse monoclonal anti-human/mouse Granzyme B Pacific Blue clone GB11 Biolegend Cat# 515408 RRID: AB_2562196 Rat monoclonal anti-mouse Ly-6C FITC clone HK1.4 Biolegend Cat# 128006 RRID: AB_1186134 Rat monoclonal anti-mouse Ly-6G PE clone 1A8 Biolegend Cat# 127608 RRID: AB_1186104 Mouse monoclonal anti-mouse NK1.1 PE clone PK136 Biolegend Cat# 108707 RRID: AB_313394 Mouse monoclonal anti-mouse NK1.1 BV785 clone PK136 Biolegend Cat# 108749 RRID: AB_2564304 Mouse monoclonal anti-mouse NK1.1 BUV661 clone PK136 BD Biosciences Cat# 741477 RRID: AB_2870942 Armenian hamster anti-mouse TCRβ chain APC clone H57-597 Biolegend Cat# 109211 RRID: AB_313434 Armenian hamster anti-mouse TCRβ chain BV650 clone H57-597 Biolegend Cat# 109251 RRID: AB_2810348 Armenian hamster anti-mouse TCRβ chain BV421 clone H57-597 Biolegend Cat# 109230 RRID: AB_ 2562562 Rat monoclonal anti-mouse TNF-α BV421 clone MP6-XT22 Biolegend Cat# 506327 RRID: AB_2562902 Bacterial and virus strains Subcloning EfficiencyTM DH5α Invitrogen Cat#18265017 Chemicals, peptides, and recombinant proteins Cytofix/Cytoperm fixation permeabilization kit BD Biosciences Cat#554714 cOmpleteTM, EDTA-free Protease Inhibitor Cocktail Merck Cat#11873580001 PhosSTOP, Phosphatase Inhibitors Merck Cat#4906845001 Zombie NIR Fixable viability Kit BioLegend Cat#423106 PMA SIGMA Cat#P1585 Ionomycin calcium salt SIGMA Cat#I0634 Protein Transport Inhibitor (containing Brefeldin A) BD Biosciences Cat#555029 IQTM SYBR Green Supermix BIO-RAD Cat#1708882 Lymphoprep STEMCELL Technologies Cat#15257179 MACS SmartStrainer (70um) Miltenyi Biotec Cat#130-098-462 D-Luciferin Promega Cat#L2916 A485 MCE Cat#HY-107455 PEI 25 kDa Sigma Cat#408727 PEG8000 Sigma Aldrich Cat#P5413 OPTIPREP (Iodixanol) Axis Shield Cat#415468 Ultra-15 mL Amicon® columns Millipore Cat#C7715 OptiprepTM Serumwerk Bernburg Cat#1893 ACK Lysing Buffer Invitrogen Cat# A1049201 Collagenase D Roche Cat# 11088866001 DNAse I Roche 11 284 932 001 DMEM with Glutamax Gibco Cat# 61965-026 OptiMEM Gibco Cat #51985026 Lipofectamine3000 Invitrogen Cat# L3000 Formaldehide PanReac AppliChem Cas 50-00-0 Eukitt® Quick-hardening mounting medium Sigma-Aldrich Cat#03989 Cas 25608-33-7 (Continued on next page) e3 Cancer Cell 44, 1–17.e1–e12, May 11, 2026

    Polymer:

    Article Title: Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity
    Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit Polyclonal anti-human H3K27ac Abcam Cat# ab4729; RRID: AB_2118291 Rabbit Monoclonal anti-human YY1 (SY29-01) Invitrogen Cat# MA5-32052; RRID: AB_2809346 Rat monoclonal IgG2b isotype control (clone LTF-2) Bioxcell Cat#BE0090; RRID: AB_1107780 Rat monoclonal anti-mouse CD4 (clone GK1.5) Bioxcell Cat#BE0003-1; RRID: AB_1107636 Rat monoclonal anti-mouse CD8α (clone 2.43) Bioxcell Cat#BE0061; RRID: AB_1125541 Rat monoclonal anti-mouse CD8β (Lyt 3.2, clone 53-5.8) Bioxcell Cat#BE0223; RRID: AB_2687706 Rat monoclonal anti-mouse CD19 (clone 1D3) Bioxcell Cat#BE0150; RRID: AB_10949187 Rat monoclonal anti-mouse NK1.1 (clone PK136) Bioxcell Cat#BE0036; RRID: AB_1107737 Rat monoclonal anti-mouse CSF1R (CD115, clone AFS98) Bioxcell Cat#BE0213; RRID: AB_2687699 Rat monoclonal anti-mouse Ly6G (clone 1A8) Bioxcell CatBE0075-1; RRID: AB_1107721 Rat monoclonal anti-mouse CTLA-4 (CD152, clone 9D9) Bioxcell Cat#BE0164; RRID: AB_10949609 Rat monoclonal anti-mouse PD-1 (CD279) clone 29F.1A12 Bioxcell Cat#BE0273; RRID: AB_2687796 Rat monoclonal anti-mouse IFNAR-1 clone MAR1-5A3 Bioxcell Cat#BE0241; RRID: AB_2687723 Rat monoclonal anti-mouse IFNγ clone XMG1.2 Bioxcell Cat#BE0055; RRID: AB_1107694 Armenian hamster anti-mouse Fas Ligand (CD178) clone MFL3 Bioxcell Cat#BE0319; RRID: AB_2819046 Rabbit polyclonal anti-GFP Abcam Cat#ab6556; RRID: AB_305564 Rabbit monoclonal anti-mouse Fas clone EPR24898-74 Abcam Cat#ab271016 RRID: AB_3712731 Goat anti-rabbit labeled polymer EnVisionTM+ System Dako Cat#K400311-2 Rabbit monoclonal anti-mouse CD8α clone D4W2Z Cell Signaling Cat#98941 RRID:AB_2756376 Rabbit monoclonal anti-mouse FoxP3 clone D608R Cell Signaling Cat#12653 RRID: AB_2797979 Rabbit monoclonal anti-mouse CD31 clone D8V9E Cell Signaling Cat#77699 RRID: AB_2722705 Rabbit monoclonal anti-mouse ICAM1 clone EPR16608 Abcam Cat#ab179707 RRID:AB_2814769 Rat monoclonal anti-mouse CD4 BUV496 clone GK1.5 BD Biosciences Cat#612952; RRID: AB_2813886 Rat monoclonal anti-mouse CD8α BUV395 clone 53-6.7 BD Biosciences Cat# 563786; RRID: AB_2732919 (Continued on next page) e1 Cancer Cell 44, 1–17.e1–e12, May 11, 2026 .. REAGENT or RESOURCE SOURCE IDENTIFIER Mouse monoclonal anti-human/mouse Granzyme B Pacific Blue clone GB11 Biolegend Cat# 515408 RRID: AB_2562196 Rat monoclonal anti-mouse Ly-6C FITC clone HK1.4 Biolegend Cat# 128006 RRID: AB_1186134 Rat monoclonal anti-mouse Ly-6G PE clone 1A8 Biolegend Cat# 127608 RRID: AB_1186104 Mouse monoclonal anti-mouse NK1.1 PE clone PK136 Biolegend Cat# 108707 RRID: AB_313394 Mouse monoclonal anti-mouse NK1.1 BV785 clone PK136 Biolegend Cat# 108749 RRID: AB_2564304 Mouse monoclonal anti-mouse NK1.1 BUV661 clone PK136 BD Biosciences Cat# 741477 RRID: AB_2870942 Armenian hamster anti-mouse TCRβ chain APC clone H57-597 Biolegend Cat# 109211 RRID: AB_313434 Armenian hamster anti-mouse TCRβ chain BV650 clone H57-597 Biolegend Cat# 109251 RRID: AB_2810348 Armenian hamster anti-mouse TCRβ chain BV421 clone H57-597 Biolegend Cat# 109230 RRID: AB_ 2562562 Rat monoclonal anti-mouse TNF-α BV421 clone MP6-XT22 Biolegend Cat# 506327 RRID: AB_2562902 Bacterial and virus strains Subcloning EfficiencyTM DH5α Invitrogen Cat#18265017 Chemicals, peptides, and recombinant proteins Cytofix/Cytoperm fixation permeabilization kit BD Biosciences Cat#554714 cOmpleteTM, EDTA-free Protease Inhibitor Cocktail Merck Cat#11873580001 PhosSTOP, Phosphatase Inhibitors Merck Cat#4906845001 Zombie NIR Fixable viability Kit BioLegend Cat#423106 PMA SIGMA Cat#P1585 Ionomycin calcium salt SIGMA Cat#I0634 Protein Transport Inhibitor (containing Brefeldin A) BD Biosciences Cat#555029 IQTM SYBR Green Supermix BIO-RAD Cat#1708882 Lymphoprep STEMCELL Technologies Cat#15257179 MACS SmartStrainer (70um) Miltenyi Biotec Cat#130-098-462 D-Luciferin Promega Cat#L2916 A485 MCE Cat#HY-107455 PEI 25 kDa Sigma Cat#408727 PEG8000 Sigma Aldrich Cat#P5413 OPTIPREP (Iodixanol) Axis Shield Cat#415468 Ultra-15 mL Amicon® columns Millipore Cat#C7715 OptiprepTM Serumwerk Bernburg Cat#1893 ACK Lysing Buffer Invitrogen Cat# A1049201 Collagenase D Roche Cat# 11088866001 DNAse I Roche 11 284 932 001 DMEM with Glutamax Gibco Cat# 61965-026 OptiMEM Gibco Cat #51985026 Lipofectamine3000 Invitrogen Cat# L3000 Formaldehide PanReac AppliChem Cas 50-00-0 Eukitt® Quick-hardening mounting medium Sigma-Aldrich Cat#03989 Cas 25608-33-7 (Continued on next page) e3 Cancer Cell 44, 1–17.e1–e12, May 11, 2026

    Saline:

    Article Title: Hypoxic-ischemic brain injury in neonatal mice sequentially recruits neutrophils with dichotomous phenotype and function.
    Article Snippet: .. Specifically, 5 μg/g body weight anti-Ly6G (clone 1A8, BioXCell, USA) were administered intraperitoneally (i.p.) in 10 μl/g body weight phosphate buffered saline (PBS) either 12 h/36 h/50 h (early depletion) or 6/7/8 days (late depletion) after HI. .. Anti-rat kappa immunoglobulin (5 μg/g body weight, clone MAR 18.5, BioXCell) was administered 1-2 h after the first and the third anti-Ly6G treatment.

    Article Title: Hypoxic-ischemic brain injury in neonatal mice sequentially recruits neutrophils with dichotomous phenotype and function
    Article Snippet: .. Specifically, 5 μg/g body weight anti-Ly6G (clone 1A8, BioXCell, USA) were administered intraperitoneally (i.p.) in 10 μl/g body weight phosphate buffered saline (PBS) either 12 h/36 h/50 h (early depletion) or 6/7/8 days (late depletion) after HI. .. Anti-rat kappa immunoglobulin (5 μg/g body weight, clone MAR 18.5, BioXCell) was administered 1-2 h after the first and the third anti-Ly6G treatment.

    Injection:

    Article Title: Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity
    Article Snippet: .. CD16B-CD32A +/− /γ +/− male mice received 350 μg/mouse anti-Ly6G (clone 1A8, Bio X Cell, cat. #BP0075-1) for neutrophil depletion or isotype control rat IgG2a, κ (clone 2A3, Bio X Cell, cat. #BP0089) intraperitoneally on days −2 and −1 prior to OTI/OTII injection, then every 2 days thereafter. .. CD16B-CD32A +/− /γ +/− male mice received 350 μg/mouse anti-Ly6G (clone 1A8, Bio X Cell, cat. #BP0075-1) for neutrophil depletion or isotype control rat IgG2a, κ (clone 2A3, Bio X Cell, cat. #BP0089) intraperitoneally on days −2 and −1 prior to OTI/OTII injection, then every 2 days thereafter.

    Article Title: Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Anti-Tumor Immunity
    Article Snippet: .. D ow nloaded from http://aacrjournals.org/cancerrescom m un/article-pdf/doi/10.1158/2767-9764.C R C -25-0509/3736552/crc-25-0509.pdf by guest on 16 February 2026 8 Cell depletion in vivo CD16B-CD32A+/−/γ+/− male mice received 350 μg/mouse anti-Ly6G (clone 1A8, BioXCell Cat# BP0075-1) for neutrophil depletion or isotype control rat IgG2a, κ (clone 2A3, BioXcell Cat# BP0089) i.p. on days -2 and -1 prior to OTI/OTII injection, then every 2 days thereafter. .. Depletion was confirmed in the spleen and peripheral blood by flow cytometry using intracellular staining of anti-Ly6G (BioLegend Cat# 127612, RRID:AB_2251161).

    In Vivo:

    Article Title: Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Anti-Tumor Immunity
    Article Snippet: .. D ow nloaded from http://aacrjournals.org/cancerrescom m un/article-pdf/doi/10.1158/2767-9764.C R C -25-0509/3736552/crc-25-0509.pdf by guest on 16 February 2026 8 Cell depletion in vivo CD16B-CD32A+/−/γ+/− male mice received 350 μg/mouse anti-Ly6G (clone 1A8, BioXCell Cat# BP0075-1) for neutrophil depletion or isotype control rat IgG2a, κ (clone 2A3, BioXcell Cat# BP0089) i.p. on days -2 and -1 prior to OTI/OTII injection, then every 2 days thereafter. .. Depletion was confirmed in the spleen and peripheral blood by flow cytometry using intracellular staining of anti-Ly6G (BioLegend Cat# 127612, RRID:AB_2251161).



    Similar Products

    94
    Novus Biologicals clone 1a8
    Clone 1a8, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/clone+1a8/Gr-1%2FLy-6G+Antibody+(1A8)+%5BDyLight+550%5D/pm41838721-178-65-67
    Average 94 stars, based on 1 article reviews
    clone 1a8 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Leinco Technologies anti mouse ly 6g clone 1a8 mab
    Anti Mouse Ly 6g Clone 1a8 Mab, supplied by Leinco Technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/clone+1a8/anti+ly6g/pm41820386-243-1-9
    Average 86 stars, based on 1 article reviews
    anti mouse ly 6g clone 1a8 mab - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    95
    Bio X Cell clone 1a8
    αCD16-Ova–induced T-cell expansion in the spleen requires neutrophils and MHC on neutrophils, whereas Batf3 + cDC1s and splenic macrophages are dispensable. Mice were treated as in , and the role of neutrophils ( A and B ), MHC-I on neutrophils ( C and D ), and the contribution of cDC1 ( E and F ) and splenic macrophages ( G and H ) in αCD16-Ova–mediated T-cell proliferation was evaluated. A and B, Role of neutrophils. Treatment with <t>1A8</t> resulted in marked neutrophil depletion in blood but only partial depletion in the spleen ( A ), with a corresponding partial reduction in splenic CD8 OT-I and CD4 OT-II T-cell proliferation ( B ). C and D, Requirement for neutrophil MHC-I. In CD16B/γ −/− mice with neutrophil-specific MHC-I deletion <t>(Ly6G-Cre/MHC-I</t> fl/fl ), MHC-I expression was partially reduced on splenic neutrophils but intact on cDC1s ( C ); isotype control was used to set gates. CD8 OT-I proliferation was proportionally reduced in Ly6G-Cre/MHC-I fl/fl , consistent with incomplete MHC-I deletion in neutrophils ( D ). E and F, Requirement for Batf3 + cDC1s. In CD16B/γ −/− mice with a deletion in Batf3 (CD16B/γ −/− Batf3 −/− ), there was a marked loss of cDC1 but intact cDC2 populations ( E ). cDC1 loss did not affect αCD16-Ova induced CD8 OT-I or CD4 OT-II T-cell proliferation ( F ). G and H, Anti-CD115 antibody–mediated immunodepletion resulted in a significant but partial reduction of F4/80 + macrophages in the spleen compared with isotype control I (Ctr) treatment ( G ). CD115 antibody treatment did not alter αCD16-Ova–induced CD8 T-cell proliferation ( H ). Sp, spleen. Data are presented as mean ± SEM. Two-group comparisons were done using an unpaired two-tailed Student t test; comparisons among ≥3 groups were done using one-way ANOVA with Tukey post hoc test. Significance was defined as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Ab, antibody; KO, knockout.
    Clone 1a8, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/clone+1a8/InVivoPlus+anti-mouse+Ly6G+Ly6C/pmc13012031-73-10-12
    Average 95 stars, based on 1 article reviews
    clone 1a8 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    90
    Bio X Cell antily6g clone 1a8
    αCD16-Ova–induced T-cell expansion in the spleen requires neutrophils and MHC on neutrophils, whereas Batf3 + cDC1s and splenic macrophages are dispensable. Mice were treated as in , and the role of neutrophils ( A and B ), MHC-I on neutrophils ( C and D ), and the contribution of cDC1 ( E and F ) and splenic macrophages ( G and H ) in αCD16-Ova–mediated T-cell proliferation was evaluated. A and B, Role of neutrophils. Treatment with <t>1A8</t> resulted in marked neutrophil depletion in blood but only partial depletion in the spleen ( A ), with a corresponding partial reduction in splenic CD8 OT-I and CD4 OT-II T-cell proliferation ( B ). C and D, Requirement for neutrophil MHC-I. In CD16B/γ −/− mice with neutrophil-specific MHC-I deletion <t>(Ly6G-Cre/MHC-I</t> fl/fl ), MHC-I expression was partially reduced on splenic neutrophils but intact on cDC1s ( C ); isotype control was used to set gates. CD8 OT-I proliferation was proportionally reduced in Ly6G-Cre/MHC-I fl/fl , consistent with incomplete MHC-I deletion in neutrophils ( D ). E and F, Requirement for Batf3 + cDC1s. In CD16B/γ −/− mice with a deletion in Batf3 (CD16B/γ −/− Batf3 −/− ), there was a marked loss of cDC1 but intact cDC2 populations ( E ). cDC1 loss did not affect αCD16-Ova induced CD8 OT-I or CD4 OT-II T-cell proliferation ( F ). G and H, Anti-CD115 antibody–mediated immunodepletion resulted in a significant but partial reduction of F4/80 + macrophages in the spleen compared with isotype control I (Ctr) treatment ( G ). CD115 antibody treatment did not alter αCD16-Ova–induced CD8 T-cell proliferation ( H ). Sp, spleen. Data are presented as mean ± SEM. Two-group comparisons were done using an unpaired two-tailed Student t test; comparisons among ≥3 groups were done using one-way ANOVA with Tukey post hoc test. Significance was defined as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Ab, antibody; KO, knockout.
    Antily6g Clone 1a8, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/clone+1a8/anti+ly6g+clone+1a8/pm40614206-355-10-11
    Average 90 stars, based on 1 article reviews
    antily6g clone 1a8 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Bio X Cell anti-ly6g antibody clone 1a8
    αCD16-Ova–induced T-cell expansion in the spleen requires neutrophils and MHC on neutrophils, whereas Batf3 + cDC1s and splenic macrophages are dispensable. Mice were treated as in , and the role of neutrophils ( A and B ), MHC-I on neutrophils ( C and D ), and the contribution of cDC1 ( E and F ) and splenic macrophages ( G and H ) in αCD16-Ova–mediated T-cell proliferation was evaluated. A and B, Role of neutrophils. Treatment with <t>1A8</t> resulted in marked neutrophil depletion in blood but only partial depletion in the spleen ( A ), with a corresponding partial reduction in splenic CD8 OT-I and CD4 OT-II T-cell proliferation ( B ). C and D, Requirement for neutrophil MHC-I. In CD16B/γ −/− mice with neutrophil-specific MHC-I deletion <t>(Ly6G-Cre/MHC-I</t> fl/fl ), MHC-I expression was partially reduced on splenic neutrophils but intact on cDC1s ( C ); isotype control was used to set gates. CD8 OT-I proliferation was proportionally reduced in Ly6G-Cre/MHC-I fl/fl , consistent with incomplete MHC-I deletion in neutrophils ( D ). E and F, Requirement for Batf3 + cDC1s. In CD16B/γ −/− mice with a deletion in Batf3 (CD16B/γ −/− Batf3 −/− ), there was a marked loss of cDC1 but intact cDC2 populations ( E ). cDC1 loss did not affect αCD16-Ova induced CD8 OT-I or CD4 OT-II T-cell proliferation ( F ). G and H, Anti-CD115 antibody–mediated immunodepletion resulted in a significant but partial reduction of F4/80 + macrophages in the spleen compared with isotype control I (Ctr) treatment ( G ). CD115 antibody treatment did not alter αCD16-Ova–induced CD8 T-cell proliferation ( H ). Sp, spleen. Data are presented as mean ± SEM. Two-group comparisons were done using an unpaired two-tailed Student t test; comparisons among ≥3 groups were done using one-way ANOVA with Tukey post hoc test. Significance was defined as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Ab, antibody; KO, knockout.
    Anti Ly6g Antibody Clone 1a8, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/clone+1a8/anti+ly6g+clone+1a8/pm40574311-36-7-18
    Average 90 stars, based on 1 article reviews
    anti-ly6g antibody clone 1a8 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    αCD16-Ova–induced T-cell expansion in the spleen requires neutrophils and MHC on neutrophils, whereas Batf3 + cDC1s and splenic macrophages are dispensable. Mice were treated as in , and the role of neutrophils ( A and B ), MHC-I on neutrophils ( C and D ), and the contribution of cDC1 ( E and F ) and splenic macrophages ( G and H ) in αCD16-Ova–mediated T-cell proliferation was evaluated. A and B, Role of neutrophils. Treatment with 1A8 resulted in marked neutrophil depletion in blood but only partial depletion in the spleen ( A ), with a corresponding partial reduction in splenic CD8 OT-I and CD4 OT-II T-cell proliferation ( B ). C and D, Requirement for neutrophil MHC-I. In CD16B/γ −/− mice with neutrophil-specific MHC-I deletion (Ly6G-Cre/MHC-I fl/fl ), MHC-I expression was partially reduced on splenic neutrophils but intact on cDC1s ( C ); isotype control was used to set gates. CD8 OT-I proliferation was proportionally reduced in Ly6G-Cre/MHC-I fl/fl , consistent with incomplete MHC-I deletion in neutrophils ( D ). E and F, Requirement for Batf3 + cDC1s. In CD16B/γ −/− mice with a deletion in Batf3 (CD16B/γ −/− Batf3 −/− ), there was a marked loss of cDC1 but intact cDC2 populations ( E ). cDC1 loss did not affect αCD16-Ova induced CD8 OT-I or CD4 OT-II T-cell proliferation ( F ). G and H, Anti-CD115 antibody–mediated immunodepletion resulted in a significant but partial reduction of F4/80 + macrophages in the spleen compared with isotype control I (Ctr) treatment ( G ). CD115 antibody treatment did not alter αCD16-Ova–induced CD8 T-cell proliferation ( H ). Sp, spleen. Data are presented as mean ± SEM. Two-group comparisons were done using an unpaired two-tailed Student t test; comparisons among ≥3 groups were done using one-way ANOVA with Tukey post hoc test. Significance was defined as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Ab, antibody; KO, knockout.

    Journal: Cancer Research Communications

    Article Title: Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity

    doi: 10.1158/2767-9764.CRC-25-0509

    Figure Lengend Snippet: αCD16-Ova–induced T-cell expansion in the spleen requires neutrophils and MHC on neutrophils, whereas Batf3 + cDC1s and splenic macrophages are dispensable. Mice were treated as in , and the role of neutrophils ( A and B ), MHC-I on neutrophils ( C and D ), and the contribution of cDC1 ( E and F ) and splenic macrophages ( G and H ) in αCD16-Ova–mediated T-cell proliferation was evaluated. A and B, Role of neutrophils. Treatment with 1A8 resulted in marked neutrophil depletion in blood but only partial depletion in the spleen ( A ), with a corresponding partial reduction in splenic CD8 OT-I and CD4 OT-II T-cell proliferation ( B ). C and D, Requirement for neutrophil MHC-I. In CD16B/γ −/− mice with neutrophil-specific MHC-I deletion (Ly6G-Cre/MHC-I fl/fl ), MHC-I expression was partially reduced on splenic neutrophils but intact on cDC1s ( C ); isotype control was used to set gates. CD8 OT-I proliferation was proportionally reduced in Ly6G-Cre/MHC-I fl/fl , consistent with incomplete MHC-I deletion in neutrophils ( D ). E and F, Requirement for Batf3 + cDC1s. In CD16B/γ −/− mice with a deletion in Batf3 (CD16B/γ −/− Batf3 −/− ), there was a marked loss of cDC1 but intact cDC2 populations ( E ). cDC1 loss did not affect αCD16-Ova induced CD8 OT-I or CD4 OT-II T-cell proliferation ( F ). G and H, Anti-CD115 antibody–mediated immunodepletion resulted in a significant but partial reduction of F4/80 + macrophages in the spleen compared with isotype control I (Ctr) treatment ( G ). CD115 antibody treatment did not alter αCD16-Ova–induced CD8 T-cell proliferation ( H ). Sp, spleen. Data are presented as mean ± SEM. Two-group comparisons were done using an unpaired two-tailed Student t test; comparisons among ≥3 groups were done using one-way ANOVA with Tukey post hoc test. Significance was defined as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Ab, antibody; KO, knockout.

    Article Snippet: CD16B-CD32A +/− /γ +/− male mice received 350 μg/mouse anti-Ly6G (clone 1A8, Bio X Cell, cat. #BP0075-1) for neutrophil depletion or isotype control rat IgG2a, κ (clone 2A3, Bio X Cell, cat. #BP0089) intraperitoneally on days −2 and −1 prior to OTI/OTII injection, then every 2 days thereafter.

    Techniques: Expressing, Control, Immunodepletion, Two Tailed Test, Knock-Out